

### PERSONAL INFORMATION

**Loreta Kondili**

### WORK EXPERIENCE

---

January 2018- Present

#### Researcher

Istituto Superiore di Sanità (Italy)

Clinical evaluation of Medical devices (DM) according to Directive 93/42 / EEC and subsequent amendments and In Vitro Diagnostic Medical Devices (IVD) according to per Directive 98/79 / EC and subsequent amendments.

January 2016- Present

#### Clinical Researcher

Istituto Superiore di Sanità National Center for Global Health (Italy)

Principal Investigator and Scientific Coordinator of the Italian Platform for the Study of Viral Hepatitis: PITER

January 2013-December 2015

#### Clinical Researcher Hepatologist

Istituto Superiore di Sanità. Department of Therapeutic Research and Medicines Evaluation (Italy)

Clinical Coordinator of the Italian Platform for the Study of Viral Hepatitis: PITER

July 2012- Present

#### Professor

University of Tirana-Tirana (Albania)

Professor-level position undertaking academic work in Tirana. Albania

April 2009-December 2015

#### Researcher

Istituto Superiore di Sanità. National Center for Immunobiologicals Research and Evaluation Rome (Italy)

Evaluation of effectiveness and safety of viral and bacterial vaccines based on documentation presented by drug companies. Expert of European Medicines Agency and Italian Medicines Agency

December 2005-June 2015

#### Medical Doctor. Specialist in Gastroenterology and Digestive Endoscopy

Sapienza University of Roma Department of Clinical Medicine -Rome (Italy)

Outpatients clinic and Abdominal Ultrasound Unit

Specialist in Gastroenterology with particular interest in Chronic Hepatitis: care and treatment

June 1993-December 2008

#### Researcher

Istituto Superiore di Sanità Rome (Italy)

Responsible for conducting research on epidemiology, virology and therapy of viral hepatitis infections; Responsible for application of immunoenzymatic tests for specific viral antibody responses and the development and application of gene amplification techniques for detection and characterisation of HCV-RNA in biological samples

January 2002-December 2005

#### Registrar in Gastroenterology and Digestive Endoscopy

University Medical School La Sapienza Rome (Italy)

Clinical and research activities within the specialisation programme

February 2000-February 2002

#### Internship in the diagnostic digestive endoscopy

University Medical School La Sapienza Rome Italy Department of Clinical Medicine (Italy)

Responsible for the clinical care of outpatients in the Gastroenterology Clinic

January 1996-December 1996

#### Internship in the use of abdominal ultrasound

C.T.O. Hospital Rome Italy (Italy)

January 1991-June 1993

### Physician

University Hospital Center of Tirana. (Albania)

Clinical Activities in in-patients admitted to the University Hospital Center of Tirana. Out -patients clinics. Research

## EDUCATION AND TRAINING

---

October 2011-May 2015

### Gained PhD degree

Sapienza University Medical School - Roma Italy (Italy)

The Italian research doctorate (PhD) in Experimental and Clinical Hepato-Gastroenterology.

Research on viral hepatitis in an animal model

March 2002-December 2005

### Specialist in Gastroenterology and Digestive Endoscopy

University Medical School La Sapienza Roma (Italy)

Clinical activities and Research dealing with patients with gastrointestinal diseases,

October 2002-October 2003

### Training in Liver Transplantation

Queen Elisabeth Hospital University of Birmingham Birmingham Liver Unit (United Kingdom)

Researcher. Participation and training in ward- rounds , outpatients clinics and intensive care unit dedicated to patients who had undergone liver transplantation.

March 1998-

### Recognition of the Albanian Medical degree diploma in Italy

University Medical School La Sapienza Roma (Italy)

December 1998-

### Medical Certification Examination

University Medical School La Sapienza Roma (Italy)

December 1995-October 1998

### Doctorate Degree

University Medical School of Tirana-Tirana (Albania)

Research on: "Clinical and epidemiological aspects of chronic liver disease in Albanian patients".

January 1991-November 1995

### Specialization in Gastro-Hepatology

University Medical School of Tirana-Tirana (Albania)

Clinical and research activities dealing with patients with gastrointestinal diseases

January 2017-December 2017

### Master in HTA : Evaluation and Management of Health Technologies

Catholic University of Rome (Italy)

Competencies in Health Tecnology Evaluation

## ADDITIONAL INFORMATION

---

### Expertise

Competencies in conducting multicenter cohort studies

Coordination of National and International Multicentric Studies on:Viral hepatitis, regarding epidemiology, diagnosis and therapy and on NAFLD/NASH Diagnosis and therapy.

Competencies in Diagnostic tests of Viral Hepatitis

Evaluation of efficacy and safety of biological products as vaccines immunoglobulines blood products in Registrative Dossier.

Competencies on clinical evaluation of the medical devices and in vitro diagnostic medical devices for CE certification release.

Clinical evaluation and elaboration of in vitro and in vivo virological and immunological data.

Competencies in Health Tecnology Evaluation

Competencies in Modelling of infection and disease burden of viral hepatitis and non alcoholic fatty liver

Expertise on Strategies for HCV elimination in Italy

### Publications

1: Marcellusi A, Simonelli C, Mennini FS, Kondili LA; PITER Collaborating Group available at <http://www.progettoperiter.it>. Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective

Modelling Analysis. *Appl Health Econ Health Policy*. 2021 Oct 12. doi: 10.1007/s40258-021-00677-x. Epub ahead of print. PMID: 34636024.

2: Marcellusi A, Mennini FS, Ruf M, Galli C, Aghemo A, Brunetto MR, Babudieri S, Craxi A, Andreoni M, Kondili LA. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. *Liver Int*. 2021 Sep 28. doi: 10.1111/liv.15070. Epub ahead of print. PMID: 34582627.

3: Kondili LA, Aghemo A, Andreoni M. Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary. *Ann Ist Super Sanita*. 2021 Jul-Sep;57(3):201-204. doi: 10.4415/ANN\_21\_03\_02. PMID: 34554113.

4: Kondili LA. How could Italy reach the HCV elimination by 2030? *Infez Med*. 2021 Jun 1;29(2):297-298. PMID: 34061800.

5: Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Coppola C, Ciancio A, Bruno SR, Loi M, Giorgini A, Margotti M, Cossiga V, Brancaccio G, Dallio M, De Siena M, Cannizzaro M, Cavalletto L, Massari M, Mazzitelli M, De Leo P, Laccabue D, Baiocchi L, Kondili LA. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. *BMC Infect Dis*. 2021 May 4;21(1):413. doi: 10.1186/s12879-021-06053-3. PMID: 33947337; PMCID: PMC8094561.

6: Kondili LA, Aghemo A, Andreoni M, Galli M, Rossi A, Babudieri S, Nava F, Leonardi C, Mennini FS, Gardini I, Russo FP. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. *Dig Liver Dis*. 2021 Apr 26:S1590-8658(21)00142-0. doi: 10.1016/j.dld.2021.03.026. Epub ahead of print. PMID: 33926816.

7: Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. *Dig Liver Dis*. 2021 Dec;53(12):1603-1609. doi: 10.1016/j.dld.2021.03.020. Epub 2021 Apr 21. PMID: 33893040.

8: Kondili LA, Andreoni M, Alberti A, Lobello S, Babudieri S, Roscini AS, Merolla R, Marrocco W, Craxi A. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. *Epidemics*. 2021 Mar;34:100442. doi: 10.1016/j.epidem.2021.100442. Epub 2021 Feb 11. PMID: 33607538.

9: Mennini FS, Marcellusi A, Robbins Scott S, Montilla S, Craxi A, Buti M, Gheorghe L, Ryder S, Kondili LA. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. *Liver Int*. 2021 May;41(5):934-948. doi: 10.1111/liv.14808. Epub 2021 Feb 24. PMID: 33529499; PMCID: PMC8248004.

10: Kondili LA, Craxi A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements. *Liver Int*. 2021 Apr;41(4):649-655. doi: 10.1111/liv.14796. Epub 2021 Feb 8. PMID: 33486885.

11: Djuric O, Massari M, Ottone M, Collini G, Mancuso P, Vicentini M, Nicolaci A, Zannini A, Zerbini A, Manicardi V, Kondili LA, Giorgi Rossi P. Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients. *Infect Agent Cancer*. 2021 Jan 19;16(1):5. doi: 10.1186/s13027-021-00345-8. PMID: 33468188; PMCID: PMC7816419.

- 12: Polaris Observatory Collaborators. The case for simplifying and using absolute targets for viral hepatitis elimination goals. *J Viral Hepat.* 2021 Jan;28(1):12-19. doi: 10.1111/jvh.13412. Epub 2020 Nov 4. PMID: 32979881.
- 13: Kondili LA, Blach S, Razavi H, Craxi A. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination? *Ann Ist Super Sanita.* 2020 Jul-Sep;56(3):325-329. doi: 10.4415/ANN\_20\_03\_10. PMID: 32959798.
- 14: Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, Razavi H, Waked I, Zeuzem S, Craxi A. Impact of COVID-19 on global HCV elimination efforts. *J Hepatol.* 2021 Jan;74(1):31-36. doi: 10.1016/j.jhep.2020.07.042. Epub 2020 Aug 7. PMID: 32777322; PMCID: PMC7411379.
- 15: Kondili LA, Marcellusi A, Ryder S, Craxi A. Will the COVID-19 pandemic affect HCV disease burden? *Dig Liver Dis.* 2020 Sep;52(9):947-949. doi: 10.1016/j.dld.2020.05.040. Epub 2020 May 29. PMID: 32527655; PMCID: PMC7256501.
- 16: Quaranta MG, Ferrigno L, Monti M, Filomia R, Biliotti E, Iannone A, Migliorino G, Coco B, Morisco F, Vinci M, D'Ambrosio R, Chemello L, Massari M, Ieluzzi D, Russo FP, Blanc P, Verucchi G, Puoti M, Rumi MG, Barbaro F, Santantonio TA, Federico A, Chessa L, Gentile I, Zuin M, Parruti G, Morsica G, Kondili LA; PITER Collaborating Group. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. *Hepatol Int.* 2020 May;14(3):362-372. doi: 10.1007/s12072-020-10034-0. Epub 2020 Apr 11. PMID: 32279177; PMCID: PMC7220859.
- 17: Quaranta MG, Rosato S, Ferrigno L, Amoroso DC, Monti M, Di Stefano P, Filomia R, Biliotti E, Migliorino G, Russo FP, Degaspero E, Chemello L, Brancaccio G, Blanc P, Cannizzaro M, Barbaro F, Morsica G, Licata A, Kondili LA; PITER collaborating group. Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. *Antivir Ther.* 2020;25(2):73-81. doi: 10.3851/IMP3350. PMID: 32242526.
- 18: Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. *Liver Int.* 2020 Jul;40(7):1545-1555. doi: 10.1111/liv.14408. Epub 2020 Apr 2. PMID: 32078234; PMCID: PMC7384106.
- 19: Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at [www.progettopiter.it](http://www.progettopiter.it). Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. *Pharmacoeconomics.* 2019 Feb;37(2):255-266. doi: 10.1007/s40273-018-0733-3. PMID: 30378086.
- 20: Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, Cicchetti A. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. *Expert Rev Pharmacoecon Outcomes Res.* 2019 Jun;19(3):363-374. doi: 10.1080/14737167.2019.1537784. Epub 2018 Oct 31. PMID: 30351994.
- 21: Ruggeri M, Coretti S, Romano F, Kondili LA, Vella S, Cicchetti A. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. *Value Health.* 2018 Jul;21(7):783-791. doi: 10.1016/j.jval.2017.10.021. Epub 2017 Dec 6. PMID: 30005750.
- 22: Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L,

Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxi A; PITER Collaborating Group. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? *Liver Int.* 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10. PMID: 29900654; PMCID: PMC6282782.

23: Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J Hepatol.* 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. PMID: 29886156.

24: Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol.* 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27. PMID: 29599078.

25: Karampatou A, Han X, Kondili LA, Taliani G, Ciancio A, Morisco F, Critelli RM, Baraldi E, Bernabucci V, Troshina G, Guarino M, Tagliavini S, D'Ambrosio F, Bristol L, Turco L, Rosato S, Vella S, Trenti T, Neri I, La Marca A, Manthena S, Goldstein AS, Bruno S, Bao Y, Gonzalez YS, Villa E; PITER framework investigators. Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [*J Hepatol* 68 (2018) 33-41]. *J Hepatol.* 2018 Apr;68(4):867. doi: 10.1016/j.jhep.2018.01.004. Epub 2018 Feb 1. Erratum for: *J Hepatol.* 2017 Sep 5;: PMID: 29366584.

26: Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Disegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. *PLoS One.* 2018 Jan 2;13(1):e0190803. doi: 10.1371/journal.pone.0190803. Erratum for: *PLoS One.* 2017 Feb 28;12(2):e0172159. PMID: 29293676; PMCID: PMC5749879.

27: Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammarino A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. *PLoS One.* 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. PMID: 28977040; PMCID: PMC5627924.

28: Karampatou A, Han X, Kondili LA, Taliani G, Ciancio A, Morisco F, Critelli RM, Baraldi E, Bernabucci V, Troshina G, Guarino M, Tagliavini S, D'Ambrosio F,

Bristol L, Turco L, Rosato S, Vella S, Trenti T, Neri I, La Marca A, Manthena S, Goldstein AS, Bruno S, Bao Y, Gonzalez YS, Villa E; PITER framework investigators; PITER Investigators. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. *J Hepatol.* 2017 Sep 5;S0168-8278(17)32259-6. doi: 10.1016/j.jhep.2017.08.019. Epub ahead of print. Erratum in: *J Hepatol.* 2018 Jan 20;: PMID: 28882581.

29: Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxi A, Vella S; PITER Collaborating Group. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. *Hepatology.* 2017 Dec;66(6):1814-1825. doi: 10.1002/hep.29399. Epub 2017 Oct 30. PMID: 28741307; PMCID: PMC5765396.

30: Kondili LA, Vella S, Zignego AL; PITER collaborating Group. Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice. *Liver Int.* 2018 Jan;38(1):183. doi: 10.1111/liv.13490. Epub 2017 Jul 6. PMID: 28599083.

31: Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol.* 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16. PMID: 28404132.

32: European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. *Lancet Gastroenterol Hepatol.* 2017 May;2(5):325-336. doi: 10.1016/S2468-1253(17)30045-6. Epub 2017 Mar 15. PMID: 28397696.

33: Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. *PLoS One.* 2017 Feb 28;12(2):e0172159. doi: 10.1371/journal.pone.0172159. Erratum in: *PLoS One.* 2018 Jan 2;13(1):e0190803. PMID: 28245248; PMCID: PMC5330484.

34: Kodra Y, Kondili LA, Ferraroni A, Serra MA, Caretto F, Ricci MA, Taruscio D. Parent training education program: a pilot study, involving families of children with Prader-Willi syndrome. *Ann Ist Super Sanita.* 2016 Jul-Sep;52(3):428-433. doi: 10.4415/ANN\_16\_03\_15. PMID: 27698302.

35: Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F; Special Interest Group on Personalised Hepatology of the Italian Association for the Study of the Liver (AISF); Special Interest Group on Personalised Hepatology of Italian Association for Study of Liver AISF. A "systems medicine" approach to the study of non-alcoholic fatty liver disease. *Dig Liver Dis.* 2016 Mar;48(3):333-42. doi: 10.1016/j.dld.2015.10.027. Epub 2015 Nov 14. PMID: 26698409.

36: Kondili LA, Vella S; PITER Collaborating Group. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for

chronic hepatitis C in Italy. *Dig Liver Dis.* 2015 Sep;47(9):741-3. doi: 10.1016/j.dld.2015.05.022. Epub 2015 Jun 7. PMID: 26138800.

37: Taffon S, Kondili LA, Giuseppetti R, Ciccaglione AR, Pulimanti B, Attili AF, Rapicetta M, D'Ugo E. Woodchuck hepatitis virus core gene deletions and proliferative responses of peripheral blood mononuclear cells stimulated by an immunodominant epitope: a viral immune escape in the woodchuck model of chronic hepatitis B? *Arch Virol.* 2015 Apr;160(4):1065-73. doi: 10.1007/s00705-015-2346-x. Epub 2015 Feb 10. PMID: 25666197.

38: De Santis A, Iegri C, Kondili L, Riggio O, Salvatori FM, Catalano C, Di Martino M, Bassanelli C, Lupo M, Lucatelli P, Attili AF. Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study. *Dig Liver Dis.* 2014 Aug;46(8):726-30. doi: 10.1016/j.dld.2014.04.009. Epub 2014 Jun 2. PMID: 24893685.

39: Rapicetta M, Monarca R, Kondili LA, Chionne P, Madonna E, Madeddu G, Soddu A, Candido A, Carbonara S, Mura MS, Starnini G, Babudieri S. Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy. *Infection.* 2013 Feb;41(1):69-76. doi: 10.1007/s15010-012-0385-8. Epub 2012 Dec 22. PMID: 23264095.

40: Balla I, Kondili LA, Kondili A. Risk factors among coronary heart disease patients in the context of the Albanian paradox. *Anadolu Kardiyol Derg.* 2012 Feb;12(1):82. doi: 10.5152/akd.2012.022. Epub 2012 Jan 10. PMID: 22231944.

41: D'Ugo E, Canitano A, Catone S, Giuseppetti R, Kondili LA, Argentini C, Rapicetta M. Effect of an immunogenic complex containing WHV viral particles and non-neutralizing anti-HBs antibodies on the outcome of WHV infection in woodchucks. *J Med Virol.* 2011 Jan;83(1):178-86. doi: 10.1002/jmv.21942. PMID: 21108357.

42: Taffon S, Bidini G, Vichi F, Corti G, Genovese D, Kondili LA, Bindi R, Armellini F, Leoncini F, Bartoloni A, Mazzotta F, Rapicetta M. A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy. *J Clin Virol.* 2011 Feb;50(2):142-7. doi: 10.1016/j.jcv.2010.10.011. Epub 2010 Nov 20. PMID: 21094625.

43: Kondili LA, Cuko L, Chionne P, Candido A, Madonna E, Dentico P, Resuli B, Taliani G, Brunetto MR, Rapicetta M. Hepatitis B, C and Delta virus infections in Albanian patients with chronic liver disease: evaluation of possible changes during the last 10 years. *Eur J Gastroenterol Hepatol.* 2010 Feb;22(2):167-71. doi: 10.1097/MEG.0b013e328330d410. PMID: 19734797.

44: Dettori S, Candido A, Kondili LA, Chionne P, Taffon S, Genovese D, Iudicone P, Miceli M, Rapicetta M. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. *J Infect.* 2009 Aug;59(2):128-33. doi: 10.1016/j.jinf.2009.06.007. Epub 2009 Jun 18. PMID: 19586663.

45: Monno R, Volpe A, Basho M, Fumarola L, Trerotoli P, Kondili LA, Bino S, Schinaia N, Dentico P; Albanian-Italian collaborating group. *Helicobacter pylori* seroprevalence in selected groups of Albanian volunteers. *Infection.* 2008 Aug;36(4):345-50. doi: 10.1007/s15010-008-6338-6. Epub 2008 Jun 20. PMID: 18574555.

46: Biliotti E, Kondili LA, Furlan C, Ferretti G, Zacharia S, De Angelis M, Guidi S, Gusman N, Taliani G. Acute hepatitis B in patients with or without underlying chronic HCV infection. *J Infect.* 2008 Aug;57(2):152-7. doi: 10.1016/j.jinf.2008.04.006. Epub 2008 Jun 6. PMID: 18538412.

47: Candido A, Chionne P, Milazzo L, Dettori S, Madonna E, Taffon S, Kondili LA, Barca A, Hassan HJ, Rapicetta M. Nucleic acid testing (NAT) for HCV RNA in



Italian transfusion centres: an external quality assessment. *J Clin Virol*. 2008 Apr;41(4):277-82. doi: 10.1016/j.jcv.2008.01.008. Epub 2008 Mar 5. PMID: 18321776.

48: D'Ugo E, Kondili LA, Canitano A, Catone S, Giuseppetti R, Gallinella B, Palmieri G, Orobello S, Argentini C, Gluck R, Rapicetta M. Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine. *Vaccine*. 2007 Jun 21;25(26):4895-902. doi: 10.1016/j.vaccine.2007.04.030. Epub 2007 May 4. PMID: 17531355.

49: Kondili LA, Ulqinaku D, Hajdini M, Basho M, Chionne P, Madonna E, Taliani G, Candido A, Dentico P, Bino S, Rapicetta M. Hepatitis B virus infection in health care workers in Albania: a country still highly endemic for HBV infection. *Infection*. 2007 Apr;35(2):94-7. doi: 10.1007/s15010-007-6076-1. PMID: 17401713.

50: Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, Bramhall S, Mutimer D. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. *Eur J Surg Oncol*. 2007 Sep;33(7):868-73. doi: 10.1016/j.ejso.2006.10.001. Epub 2007 Jan 26. PMID: 17258882.

51: Kondili LA, Genovese D, Argentini C, Chionne P, Toscani P, Fabro R, Cocconi R, Rapicetta M. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. *Eur J Clin Microbiol Infect Dis*. 2006 Aug;25(8):527-31. doi: 10.1007/s10096-006-0162-7. PMID: 16835740.

52: Kondili LA, Chionne P, Porcaro A, Madonna E, Taffon S, Resuli B, Taliani G, Rapicetta M. Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania. *Epidemiol Infect*. 2006 Feb;134(1):95-101. doi: 10.1017/S095026880500470X. PMID: 16409655; PMCID: PMC2870364.

53: Kondili LA, Taliani G, Cerga G, Tosti ME, Babameto A, Resuli B. Correlation of alcohol consumption with liver histological features in non-cirrhotic patients. *Eur J Gastroenterol Hepatol*. 2005 Feb;17(2):155-9. doi: 10.1097/00042737-200502000-00005. PMID: 15674092.

54: Kondili LA, Brunetto MR, Maina AM, Argentini C, Chionne P, La Sorsa V, Resuli B, Mele A, Rapicetta M. Clinical and molecular characterization of chronic hepatitis B in Albania: a country that is still highly endemic for HBV infection. *J Med Virol*. 2005 Jan;75(1):20-6. doi: 10.1002/jmv.20231. PMID: 15543588.

55: Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). *J Viral Hepat*. 2004 Sep;11(5):427-31. doi: 10.1111/j.1365-2893.2004.00504.x. PMID: 15357647.

56: Genovese D, Dettori S, Argentini C, Kondili LA, La Sorsa V, Tisone G, Angelico M, Rapicetta M. Molecular characterisation of SENV and TTV infections in hepatopathic liver-transplant patients. *Brief Report. Arch Virol*. 2004 Jul;149(7):1423-33. doi: 10.1007/s00705-004-0320-0. Epub 2004 Apr 5. PMID: 15221542.

57: Lisi D, Kondili LA, Ramieri MT, Giuseppetti R, Bruni R, Della Rocca C, De Santis A, Rapicetta M. Ultrasonography in the study of hepatocellular carcinoma in woodchucks chronically infected with WHV. *Lab Anim*. 2003 Jul;37(3):233-40. doi: 10.1258/002367703766453083. PMID: 12869286.

58: Kondili LA, Chionne P, Costantino A, Villano U, Lo Noce C, PannoZZo F, Mele A, Giampaoli S, Rapicetta M. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection



in the general population. *Gut*. 2002 May;50(5):693-6. doi: 10.1136/gut.50.5.693. PMID: 11950818; PMCID: PMC1773195.

59: Kondili LA, Pisani G, Beneduce F, Morace G, Gentili G, Ballati G, Rapicetta M. Prevalence of TT virus in healthy children and thalassaemic pediatric and young adult patients. *J Pediatr Gastroenterol Nutr*. 2001 Nov;33(5):629-32. doi: 10.1097/00005176-200111000-00025. PMID: 11740244.

60: Kondili LA, Chionne P, Dettori S, Badolato MC, Grosso A, Vania A, Rapicetta M. GB virus C/hepatitis G virus exposure in Italian pediatric and young adult thalassaemic patients. *Infection*. 2001 Aug;29(4):219-21. doi: 10.1007/s15010-001-9172-7. PMID: 11545484.

61: Maio G, d'Argenio P, Stroffolini T, Bozza A, Sacco L, Tosti ME, Intorcchia M, Fossi E, d'Alessio G, Kondili LA, Rapicetta M, Mele A. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. *J Hepatol*. 2000 Jul;33(1):116-20. doi: 10.1016/s0168-8278(00)80167-1. PMID: 10905594.

62: Kondili LA, Taliani G, Tosti ME, De Bac C, Pasquazzi C, Mele A. Methodological issues in papers on IFN therapy: time for reappraisal. *J Viral Hepat*. 2000 May;7(3):184-95. doi: 10.1046/j.1365-2893.2000.00214.x. PMID: 10849260.

63: Rapicetta M, Dettori S, Kondili L, Chionne P, Ciccaglione A, Miceli M, Mannella E. Persistence of HCV-RNA in a blood donor with negative antibody assays. *Vox Sang*. 1999;76(3):192-3. doi: 10.1159/000031049. PMID: 10341337.

64: Rapicetta M, Kondili LA, Pretolani S, Stroffolini T, Chionne P, Villano U, Madonna E, Casali F, Gasbarrini G. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. *J Med Virol*. 1999 May;58(1):49-53. doi: 10.1002/(sici)1096-9071(199905)58:1<49::aid-jmv7>3.0.co;2-c. PMID: 10223545.

65: Kondili LA, Tosti ME, Szklo M, Costantino A, Cotichini R, Resuli B, Rapicetta M, Mele A. The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case-control study in Albania. *Epidemiol Infect*. 1998 Oct;121(2):391-5. doi: 10.1017/s0950268898001216. PMID: 9825791; PMCID: PMC2809537.

66: Spada E, Ciccaglione AR, Dettori S, Chionne P, Kondili LA, Amoroso P, Guadagnino V, Greco M, Rapicetta M. Genotyping HCV isolates from Italy by type-specific PCR assay in the core region. *Res Virol*. 1998 Jul-Aug;149(4):209-18. doi: 10.1016/s0923-2516(98)80002-2. PMID: 9783336.

67: Marcellini M, Kondili LA, Comparcola D, Spada E, Sartorelli MR, Palumbo M, Rapicetta M. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. *Pediatr Infect Dis J*. 1997 Nov;16(11):1049-53. doi: 10.1097/00006454-199711000-00009. PMID: 9384338.

68: Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca A, Piazza M. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. *Hepatology*. 1997 Oct;26(4):1006-11. doi: 10.1002/hep.510260431. PMID: 9328327.

#### Projects

Involved in the following technical reports of Istituto Superiore di Sanita' Rome

1. Clinical research and coordination of the Italian Platform for the study of the therapy of viral hepatitis "PITER
2. Clinical evaluation of the liver disease outcomes following HCV eradication.
3. Modelling of HCV, HBV, HDV, NAFLD/NASH infection and disease burden in Italy
4. Evaluation of economic consequences of HCV treatment to reach the elimination goals

- 5 Evaluation of HBV and HDV epidemiology in Italian hospital setting in a multiethnic context
6. Proposal: "Liver Mirror of Health" (Liver-Mith): a systems medicine approach to study the different clinic-pathologic implications of non-alcoholic fatty liver disease in an international prospective cohort study
7. Research activities in the evaluation of a therapeutic vaccine for treatment of chronic HBV infection using an animal model of infection (Marmota Monax).
- 8.. National Projects on epidemiology, parthenogenesis, molecular epidemiology clinical aspects and treatment of viral hepatitis.
9. Genome characterisation of HCV. A study on periodic and occasional blood donors . "First research project "Blood".
10. SEIEVA Italian Surveillance System of Acute Hepatitis

**Memberships** Member of the Italian Association for the Study of the Liver (AISF)  
Member of the European Association for the Study of the Liver (EASL)

**Other Relevant Information** HTA Summer School Organizational models of HTA for decisional process of Sanitary Systems developed by ALTEMS Catholic University "Sacro Cuore" Rome 8-10 September 2017

**SELECTED TRAINING COURSES**

Course in Economic Evaluation and Decisional Modelling per l'Health Technology Assessment. ALTEMS Catholic University "Sacro Cuore" Rome (Accademic Year 2015-2016)

Course: "Hepatitis disease-burden following the introduction of DAAs and economic impact model" developed by Center Disease Analysis/Polaris Observatory Colorado USA (dal 15 Agosto al 2 Settembre 2017).

Course: "Introductory course on Systematic Reviews", developed by the Italian Ministry of Health; 25-26 March 2002

Advanced course on Statistical methods in Epidemiology; developed by the Istituto Superiore di Sanita; June 1997

Course "Package for statistical analysis of data developed by Istituto Superiore di Sanita. (28- 31 October 1997).

Advanced course on Epidemiology; developed by the Istituto Superiore di Sanita; September 1996

**LANGUAGES**

**MOTHER TONGUE** Albanian

**OTHER LANGUAGES**

	Italian	English
Reading skills	Excellent	Excellent
Writing skills	Excellent	Good
Verbal skills	Excellent	Good